McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and ...

Michael Cherny has given his Buy rating due to a combination of factors including McKesson’s strong financial performance in the second quarter of fiscal year 2025. The company reported an adjusted ...

1 Day MCK 0.90% DJIA 0.59% S&P 500 0.38% Retail/Wholesale -2.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the ...

Shares of McKesson climbed after the drug distributor raised its fiscal-year guidance and reported strong sales growth during its fiscal second quarter. The stock was up 11%, at $610.99, in midday ...

McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains ...

McKesson (NYSE:MCK) reported better-than-expected second-quarter financial results on Wednesday. McKesson reported quarterly ...

McKesson's earnings for its fiscal 2025 second ... and heightened demand for specialty products and GLP-1 medications. The company also finalized partnerships with significant entities ...

Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S.

Irving, Texas-based McKesson Corporation (MCK ... driven by growth in the distribution of specialty products to providers and health systems. It also raised its adjusted EPS guidance to $31. ...

McKesson Corporation (NYSE: MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson’s Investor Relatio ...

The latest trading session saw McKesson (MCK) ending at $513.67, denoting a +0.86% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%.